Top in endocrinology: Pharma execs testify on insulin prices; semaglutide vs. dulaglutide
Click Here to Manage Email Alerts
Pharmaceutical executives fielded questions on the costs of insulin and other prescription drugs during a recent hearing of the U.S. Senate Committee on Health, Education, Labor and Pensions.
“I think anybody who has listened to this hearing has concluded that the system is broken,” Sen. Bernie Sanders, I-Vt, chairman of the committee, said during the hearing. “It is enormously complicated. There’s virtually no transparency.”
It was the top story in endocrinology last week.
Another top story reported study data that showed after switching from Saxenda (liraglutide, Novo Nordisk) to Ozempic/Wegovy (semaglutide, Novo Nordisk), adults with type 2 diabetes had greater reductions in HbA1c and body weight at 26 weeks than those who had switched to Trulicity (dulaglutide, Eli Lilly). Researchers reported that adults who switched to dulaglutide saw no change in body weight or HbA1c.
Read these and more top stories in endocrinology below:
US Senate committee questions leading pharmaceutical companies, PBMs on insulin pricing
Members of the U.S. Senate Committee on Health, Education, Labor and Pensions conducted a hearing on May 10 to investigate insulin affordability and what caused prices to increase during the past decade. Read more.
Semaglutide provides more weight loss, larger HbA1c reduction than dulaglutide in diabetes
Adults with type 2 diabetes who switched from liraglutide to semaglutide therapy had greater reductions in HbA1c and body weight at 26 weeks than those who switched to dulaglutide, according to study data from researchers in Japan. Read more.
VIDEO: How to overcome social determinants of health and improve diabetes care
In this video exclusive, Jonathan D. Leffert, MD, talks with Alyson K. Myers, MD, about disparities people with diabetes face and how those social determinants of health impact outcomes. Watch video.
Time in range similar with fast-acting vs. standard insulin for young kids with diabetes
Fast-acting insulin aspart delivered through a hybrid closed-loop insulin delivery system provided similar glycemic outcomes as standard insulin aspart for young children with type 1 diabetes, according to study data. Read more.
High comorbidity burden among men with subsequent osteoporotic fractures
Among men aged at least 40 years who experienced a fracture, most with subsequent fractures in the next 2 years had cardiometabolic comorbidities and used medications linked to increased fall risk, according to researchers. Read more.